Commercial stage company focused on rare diseases. Topline placebo-controlled Ph3 LOGICS data expected Q3 for RECORLEV™, cortisol synthesis inhibitor for endogenous Cushing's syndrome. Enrollment completion announced May 11, 2020. KEVEYIS® is first and only approved drug for Primary Periodic Paralysis (PPP); Q1'20 revenue up 54% from Q1'19 and guiding to FY20 revenue of $22M-$26M.
US - Middle Atlantic
Central Nervous System, Rare Disease
100MM - 500MM
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
Top 10 Holders of Strongbridge Biopharma plc
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by